EMA
approval
· 2021-11-12
First-in-class medicine recommended for treatment of rare blood vessel inflammation
Summary
EMA recommends first-in-class medicine for treatment of a rare blood vessel inflammation, signaling a potential new option for patients with this condition.
Upgrade for the full analysis, importance score, and drug timeline.